Roanna Ruiz
Stock Analyst at Leerink Partners
(0.86)
# 3,926
Out of 5,182 analysts
60
Total ratings
35%
Success rate
-17.29%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $83 → $84 | $66.73 | +25.88% | 2 | Feb 26, 2026 | |
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $1.98 | +1.01% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $6.04 | +49.01% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.38 | +407.25% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $7.05 | +155.32% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.59 | -37.11% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $9.06 | +120.75% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $8.30 | +225.30% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $4.13 | +214.77% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.94 | +135.69% | 1 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $330 | $564.81 | -41.57% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $42.49 | -41.16% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $13.14 | +272.91% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $5.76 | +4.17% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $32.99 | -42.41% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $76.10 | +57.69% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $7.97 | +527.35% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $14.74 | +171.37% | 6 | Oct 19, 2022 |
Cytokinetics
Feb 26, 2026
Maintains: Outperform
Price Target: $83 → $84
Current: $66.73
Upside: +25.88%
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $1.98
Upside: +1.01%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $6.04
Upside: +49.01%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.38
Upside: +407.25%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $7.05
Upside: +155.32%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.59
Upside: -37.11%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $9.06
Upside: +120.75%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $8.30
Upside: +225.30%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $4.13
Upside: +214.77%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.94
Upside: +135.69%
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $564.81
Upside: -41.57%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $42.49
Upside: -41.16%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $13.14
Upside: +272.91%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $5.76
Upside: +4.17%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $32.99
Upside: -42.41%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $76.10
Upside: +57.69%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $7.97
Upside: +527.35%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $14.74
Upside: +171.37%